TAR-200 Monotherapy Promising for BCG-Unresponsive Bladder Cancer

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on Aug 21, 2025.

via HealthDay

THURSDAY, Aug. 21, 2025 -- For patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC), an intravesical gemcitabine-releasing system, TAR-200 monotherapy, is well tolerated with a high complete response (CR) rate, according to a study published online July 30 in the Journal of Clinical Oncology.

Siamak Daneshmand, M.D., from the University of Southern California Norris Comprehensive Cancer Center in Los Angeles, and colleagues conducted a phase 2b parallel cohort study involving patients with BCG-unresponsive carcinoma in situ with/without papillary disease who received TAR-200 monotherapy, TAR-200 plus cetrelimab, or cetrelimab monotherapy (cohorts [C] 2, 1, and 3, respectively). In addition, patients with BCG-unresponsive high-risk papillary disease-only NMIBC received TAR-200 monotherapy (C4).

Overall, 53, 85, 28, and 52 patients were treated in C1 to C4, respectively, as of data cutoff. The researchers found that the CR rate and median duration of response were 82.4 percent and 25.8 months, respectively, in C2. The six-, nine-, and 12-month disease-free survival rates were 85.3, 81.1, and 70.2 percent, respectively, in C4. CR rates were 67.9 and 46.4 percent in C1 and C3, respectively. In C2, C4, C1, and C3, rates of grade ≥3 treatment-related adverse events were 12.9, 13.5, 37.7, and 7.1 percent, respectively, and rates of serious treatment-related adverse events were 5.9, 5.8, 15.1, and 3.6 percent, respectively. There were no treatment-related deaths.

"The theory behind this study was that the longer the medicine sits inside the bladder, the more deeply it would penetrate the bladder and the more cancer it would destroy," Daneshmand said in a statement. "It appears that having the chemotherapy released slowly over weeks rather than in just a few hours is a much more effective approach."

Several authors disclosed ties to pharmaceutical companies, including Johnson & Johnson; the study was funded by Janssen Research & Development, a Johnson & Johnson company.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-08-22 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords